Wenbo Meng
Wenbo Meng is an expert in Gastroenterology at First Hospital of Lanzhou University (China). As of October 2026, ScienceLeadR ranks Wenbo Meng in the top 1% of experts worldwide for Gallbladder Diseases, Biliary Tract Diseases and Bile Duct Diseases. Wenbo Meng has authored 202 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 6 of them ongoing. SLR score: 1,317 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Oncology - Biochemistry - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026First Hospital of Lanzhou University
2013 - 2026
Lanzhou University
2016 - 2026
Lanzhou University Second Hospital
2023 - 2026
Number : 202
Citations
Main journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation NCT07774897 — endocrine system, sleep, fatigue syndrome, chronic, health status, lipid metabolism disorders, maintenance, prebiotics, fatigue, parasomnias, sleep initiation and maintenance disorders, glucose metabolism disorders, endocrine system diseases, lipids | N/A | Not yet recruiting | 2026 |
| The Optimal Measurement Time for the New Gallbladder Function Assessment Method NCT07321431 — research design, administration, oral, eggs, gallbladder, olive oil | N/A | Recruiting | 2026 |
| Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) NCT07165951 — injections, growth, transforming growth factors, paclitaxel, pharmaceutical preparations, transforming growth factor beta, adenocarcinoma, drug therapy, capsules, therapeutics, chemotherapy | Phase 3 | Recruiting | 2025 |
| Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer NCT07091526 — pancreatic neoplasms, uric acid, blood, serum, pancreaticoduodenectomy, neoplasms, pancreatectomy | N/A | Recruiting | 2025 |
| A Strategy for Gallstone Expulsion Through Dietary Therapy NCT06699030 — administration, oral, gallstones, cholecystitis, gallbladder, cholecystolithiasis, therapeutics, fatty acids | N/A | Recruiting | 2024 |
LeadR Networks
Main global connection map